Breakthrough trial tests Dual-Action treatment for most severe schizophrenia cases
NCT ID NCT05240976
Summary
This study is testing whether adding an anti-inflammatory drug to an existing brain-targeting medication can help people with severe schizophrenia that hasn't responded to standard treatments. The trial will involve 80 participants who will continue their current medication while receiving either the new combination or a placebo for 12 weeks. Researchers will measure changes in thinking skills, symptoms, and daily functioning to see if the combination works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.